Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS
+63.2%
Free cash flow
−112.8%

Quarter to June 2026, against a year earlier

16.13 1.94 +13.67%
Market cap
$11.3B
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
0.88
Beneish M
−5.00
Dividend safety
n/a

Summit Therapeutics PLC 10-K filed Feb 23, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:10 PM ET · Document on sec.gov · Filing index

What changed

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 24, 2025: 17 added · 19 removed · 34 modified; 8 with only figures updated